UCB

Biotechnology / Pharmaceuticals

UCB.BR

€ 87 (1.9)%

Share price

$ 17 bn

Market Cap

$ 19 bn

Enterprise Value

Carbon footprint

GHG emissions per $ 1 mln investment

0.09x the weighted average for S&P 500

FY2021

Primary Climate Goal

Proj. YOY change in GHG emissions (Scope 1 + 2)

Stronger than the -5.1% weighted average for S&P 500

FY2022

UCB aims to achieve net zero for Scope 1 + 2 by 2030

This target has not been verified as science based according to SBTi

Secondary Climate Goal

UCB aims to reduce all Scopes by 38% by 2030 from a base year 2015

<2°C

GHG emissions and Carbon intensity

UCB reported Total CO2e Emissions - Location-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2021 at 46 Kt (-2.5 /-5.2% y-o-y). Also positively, carbon intensity declined to 7.1 t (-1.1 /-13.4% y-o-y).

UCB's Scope 3 emissions decreased to 34 Kt (-4.2 /-11% y-o-y). The rate of decline has slowed vs. the previous periods (CAGR -20.6% since 4Q'18).

The company is committed to achieving net zero for Scope 1 + 2 by 2030, which translates into the estimated reduction of -5.1 Kt per annum over the period of FY2022 - FY2030. This target, however, has not been recognised as science-based (and as aligned with Paris Agreement) by the SBTi.

Date	Total CO2e emissions (location-based Scope 1 & 2) (Kt)	Scope 1	Scope 2	Scope 3	Revenue (USDm)	Carbon intensity (tons of CO2e) / (USDm)
2021Q4	46	28	18	34	6,493	7.1
2020Q4	49	31	18	38	5,916	8.2
2019Q4	59	40	18	83	5,260	11
2018Q4	62	42	21	85	5,216	12
2017Q4		26		55	4,721
2016Q4		28		55	4,218
2015Q4		56		86	2,263

UCB